Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23044265 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29687937 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29687596 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL23044120 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL29687667 | 1.00 | EIF2AK3 (1.00) | EIF2AK3EIF2S1 | |
| SCHEMBL23044302 | 0.93 | EIF2AK3 (0.87) | EIF2AK3EIF2S1 | |
| SCHEMBL29687935 | 0.93 | EIF2AK3 (0.87) | EIF2AK3EIF2S1 | |
| SCHEMBL23044322 | 0.93 | EIF2AK3 (0.87) | EIF2AK3EIF2S1 | |
| SCHEMBL23044182 | 0.93 | EIF2AK3 (0.87) | EIF2AK3EIF2S1 | |
| SCHEMBL29687992 | 0.93 | EIF2AK3 (0.87) | EIF2AK3EIF2S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | claimed |
| CN-114585606-A | PERK inhibiting compounds | 希伯塞尔股份有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-12473296-B2 | Perk inhibiting compounds | HIBERCELL, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-4021893-A1 | PERK INHIBITING COMPOUNDS | Hibercell, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-114585606-A | PERK inhibiting compounds | 希伯塞尔股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021041973-A1 | PERK INHIBITING COMPOUNDS | HIBERCELL, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332722-A1 | PERK INHIBITING COMPOUNDS | ATF4, EEF2K, ERN1 | EIF2AK3 75/4885EIF2S1 380/4885 |
| US-12473296-B2 | Perk inhibiting compounds | MAPK1, ERN1, MAP3K20 | EIF2AK3 69/4885EIF2S1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.